Inotuzumab Ozogamicin

證據等級: L5

預測適應症: 10 個

Inotuzumab Ozogamicin: From Acute Lymphoblastic Leukemia to Drug-Induced Osteoporosis

One-Sentence Summary

Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate (ADC), globally established for CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL); this specific evidence pack does not itself contain the original-indication or label text (data gap). The TxGNN model predicts possible efficacy for Drug-Induced Osteoporosis, but this is currently supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic review flags the prediction as a likely non-specific model artefact rather than a real pharmacological signal.

Quick Overview

Item	Content
Original Indication	CD22-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL) — not present in the Danish registry data (drug not marketed in Denmark); stated here from general labelling knowledge, since the evidence pack’s own `original_indications` field is empty
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	98.24%
Evidence Level	L5
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this candidate is not available in the evidence pack (flagged as a High-severity data gap). Based on known pharmacology, inotuzumab ozogamicin is an antibody-drug conjugate combining an anti-CD22 monoclonal antibody with the cytotoxic payload calicheamicin: binding to CD22 on malignant B-lymphocytes triggers internalisation of the conjugate, and calicheamicin then causes DNA double-strand breaks that kill the target cell. This mechanism is highly specific to CD22-expressing haematological malignancies.

There is no established pharmacological or clinical link between this mechanism and bone metabolism (osteoclast/osteoblast activity), and the evidence pack’s own repurposing rationale states this explicitly: no direct mechanistic connection has been identified between CD22/calicheamicin-mediated B-cell killing and drug-induced bone loss.

The high TxGNN score most likely reflects a generic knowledge-graph association rather than a drug-specific signal — cytotoxic/chemotherapeutic drug nodes are broadly connected to bone-loss-related adverse-effect nodes in the underlying graph, which can inflate similarity scores for many cytotoxic agents regardless of their actual target biology. Notably, the other top-ranked candidates in this same evidence pack (e.g. HER2-positive and luminal-subtype breast carcinoma) show the same pattern — no CD22 target expression in the relevant tissue, and in one case the attached “supporting literature” was later found to be a keyword-matching artefact (unrelated B-cell/hepatitis-B papers matched via the letter “B” in “Luminal B”). This suggests a systematic lack of specificity in this drug’s prediction set, not just an isolated weak candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Inotuzumab ozogamicin currently holds no marketing authorisation in Denmark (0 authorisations on file; market status: Not Marketed). No product-, dosage-form-, or indication-level licence data is therefore available from the Danish registry.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Antibody-Drug Conjugate (anti-CD22 antibody carrying the cytotoxic payload calicheamicin)
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Payload is a DNA-damaging cytotoxic agent; standard cytotoxic drug handling precautions should apply pending confirmation via the SmPC

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN score is high, the evidence pack’s own mechanistic review assesses the top-ranked prediction (drug-induced osteoporosis) as lacking pharmacological plausibility and likely reflecting a generic graph-topology artefact rather than a drug-specific signal. There is no supporting clinical trial or literature evidence (Evidence Level L5), the drug holds no marketing authorisation in Denmark, and label/safety data required even for an initial safety screen (S1) is missing — a Blocking-severity data gap.

To proceed, the following is needed:

TFDA/SmPC label warnings and contraindications (Blocking data gap: DG001)
Confirmed mechanism-of-action detail sourced from DrugBank or the approved label (High-priority data gap: DG002)
An independent, biologically grounded rationale linking CD22-ADC pharmacology to bone metabolism — or formal exclusion of this candidate if none can be established
Preclinical or real-world data on bone mineral density effects, if this indication is still to be pursued
A broader specificity review of this drug’s full TxGNN prediction set, given that other top-ranked candidates (breast carcinoma subtypes) show the same absence of target-expression rationale and, in one case, contaminated literature matches
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.